AIM1 promoter hypermethylation as a predictor of decreased risk of recurrence following radical prostatectomy

Prostate

Volumn 72, Issue 10, 2012, Pages 1133-1139

  Rosenbaum, Eli ^a,b   Begum, Shahnaz ^c   Brait, Mariana ^a   Zahurak, Marianna ^a   Maldonado, Leonel ^a   Mangold, Leslie A ^a   Eisenberger, Mario A ^d   Epstein, Jonathan I ^c   Partin, Alan W ^a   Sidransky, David ^a   Hoque, Mohammad O ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RABIN MEDICAL CENTER   (Israel)

^c DEPARTMENT OF PATHOLOGY   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

biomarker; DNA methylation; prostate cancer; risk of recurrence

Indexed keywords

AIM1 PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER RELAPSE; FOLLOW UP; GLEASON SCORE; HUMAN; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROMOTER REGION; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN METHYLATION; RECURRENCE RISK; REVIEW; RISK FACTOR; RISK REDUCTION;

AGED; CRYSTALLINS; DNA METHYLATION; FOLLOW-UP STUDIES; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84861576959     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22461     Document Type: Review

References (28)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ,. Cancer statistics, 2009. CA Cancer J Clin 2009; 59 (4): 225-249.
2. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC,. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003; 169 (2): 517-523.
3. Kuban DA, Thames HD, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Zietman AL,. Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys 2003; 57 (4): 915-928.
4. Kupelian PA, Elshaikh M, Reddy CA, Zippe C, Klein EA,. Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: A large single-institution experience with radical prostatectomy and external-beam radiotherapy. J Clin Oncol 2002; 20 (16): 3376-3385.
5. Sylvester JE, Blasko JC, Grimm PD, Meier R, Malmgren JA,. Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: The Seattle experience. Int J Radiat Oncol Biol Phys 2003; 57 (4): 944-952.
6. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP,. Alterations in DNA methylation: A fundamental aspect of neoplasia. Adv Cancer Res 1998; 72: 141-196.
7. Li LC, Carroll PR, Dahiya R,. Epigenetic changes in prostate cancer: Implication for diagnosis and treatment. J Natl Cancer Inst 2005; 97 (2): 103-115.
8. Boyes J, Bird A,. DNA methylation inhibits transcription indirectly via a methyl-CpG binding protein. Cell 1991; 64 (6): 1123-1134.
9. Esteller M,. CpG island hypermethylation and tumor suppressor genes: A booming present, a brighter future. Oncogene 2002; 21 (35): 5427-5440.
10. Herman JG, Baylin SB,. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003; 349 (21): 2042-2054.
11. Jones PA, Laird PW,. Cancer epigenetics comes of age. Nat Genet 1999; 21 (2): 163-167.
12. Maruyama R, Toyooka S, Toyooka KO, Virmani AK, Zochbauer-Muller S, Farinas AJ, Minna JD, McConnell J, Frenkel EP, Gazdar AF,. Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin Cancer Res 2002; 8 (2): 514-519.
13. Yamanaka M, Watanabe M, Yamada Y, Takagi A, Murata T, Takahashi H, Suzuki H, Ito H, Tsukino H, Katoh T, Sugimura Y, Shiraishi T,. Altered methylation of multiple genes in carcinogenesis of the prostate. Int J Cancer 2003; 106 (3): 382-387.
14. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB,. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996; 93 (18): 9821-9826.
15. Jeronimo C, Usadel H, Henrique R, Oliveira J, Lopes C, Nelson WG, Sidransky D,. Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J Natl Cancer Inst 2001; 93 (22): 1747-1752.
16. Sidransky D,. Emerging molecular markers of cancer. Nat Rev Cancer 2002; 2 (3): 210-219.
17. Jeronimo C, Henrique R, Hoque MO, Mambo E, Ribeiro FR, Varzim G, Oliveira J, Teixeira MR, Lopes C, Sidransky D,. A quantitative promoter methylation profile of prostate cancer. Clin Cancer Res 2004; 10 (24): 8472-8478.
18. Rosenbaum E, Hoque MO, Cohen Y, Zahurak M, Eisenberger MA, Epstein JI, Partin AW, Sidransky D,. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy. Clin Cancer Res 2005; 11 (23): 8321-8325.
19. Henrique R, Jeronimo C, Hoque MO, Nomoto S, Carvalho AL, Costa VL, Oliveira J, Teixeira MR, Lopes C, Sidransky D,. MT1G hypermethylation is associated with higher tumor stage in prostate cancer. Cancer Epidemiol Biomarkers Prev 2005; 14 (5): 1274-1278.
20. Brait M, Begum S, Carvalho AL, Dasgupta S, Vettore AL, Czerniak B, Caballero OL, Westra WH, Sidransky D, Hoque MO,. Aberrant promoter methylation of multiple genes during pathogenesis of bladder cancer. Cancer Epidemiol Biomarkers Prev 2008; 17 (10): 2786-2794.
21. Hoque MO, Kim MS, Ostrow KL, Liu J, Wisman GB, Park HL, Poeta ML, Jeronimo C, Henrique R, Lendvai A, Schuuring E, Begum S, Rosenbaum E, Ongenaert M, Yamashita K, Califano J, Westra W, van der Zee AG, Van Criekinge W, Sidransky D,. Genome-wide promoter analysis uncovers portions of the cancer methylome. Cancer Res 2008; 68 (8): 2661-2670.
22. Fearon ER, Feinberg AP, Hamilton SH, Vogelstein B,. Loss of genes on the short arm of chromosome 11 in bladder cancer. Nature 1985; 318 (6044): 377-380.
23. Olek A, Oswald J, Walter J,. A modified and improved method for bisulphite based cytosine methylation analysis. Nucleic Acids Res 1996; 24 (24): 5064-5066.
24. Kattan MW, Wheeler TM, Scardino PT,. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 1999; 17 (5): 1499-1507.
25. Kattan MW, Shariat SF, Andrews B, Zhu K, Canto E, Matsumoto K, Muramoto M, Scardino PT, Ohori M, Wheeler TM, Slawin KM,. The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. J Clin Oncol 2003; 21 (19): 3573-3579.
26. Yegnasubramanian S, Kowalski J, Gonzalgo ML, Zahurak M, Piantadosi S, Walsh PC, Bova GS, De Marzo AM, Isaacs WB, Nelson WG,. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 2004; 64 (6): 1975-1986.
27. Nagpal JK, Dasgupta S, Jadallah S, Chae YK, Ratovitski EA, Toubaji A, Netto GJ, Eagle T, Nissan A, Sidransky D, Trink B,. Profiling the expression pattern of GPI transamidase complex subunits in human cancer. Mod Pathol 2008; 21 (8): 979-991.
28. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC,. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281 (17): 1591-1597.